Trials / Active Not Recruiting
Active Not RecruitingNCT05382325
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001)
A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of MK-1484 as a Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-1484 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adults with advanced or metastatic solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MK-1484 | Subcutaneous (SC) injection |
| BIOLOGICAL | Pembrolizumab | Intravenous (IV) infusion |
Timeline
- Start date
- 2022-06-16
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
- First posted
- 2022-05-19
- Last updated
- 2024-11-14
Locations
8 sites across 4 countries: United States, Canada, Israel, Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05382325. Inclusion in this directory is not an endorsement.